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Abstract: The aim of this study was to investigate the expression of thyroid hormone receptor β1
(THRβ1) by immunohistochemistry in breast cancer (BC) tissues and to correlate the results with
clinico-biological parameters. In a well-characterized cohort of 274 primary BC patients, THRβ1
was widely expressed with a predominant nuclear location, although cytoplasmic staining was also
frequently observed. Both nuclear and cytoplasmic THRβ1 were correlated with high-risk BC markers
such as human epidermal growth factor receptor 2 (HER2), Ki67 (also known as MKI67), prominin-1
(CD133), and N-cadherin. Overall survival analysis demonstrated that cytoplasmic THRβ1 was
correlated with favourable survival (p = 0.015), whereas nuclear THRβ1 had a statistically significant
correlation with poor outcome (p = 0.038). Interestingly, in our cohort, nuclear and cytoplasmic
THRβ1 appeared to be independent markers either for poor (p = 0.0004) or for good (p = 0.048)
prognosis, respectively. Altogether, these data indicate that the subcellular expression of THRβ1 may
play an important role in oncogenesis. Moreover, the expression of nuclear THRβ1 is a negative
outcome marker, which may help to identify high-risk BC subgroups.
Keywords: thyroid hormone receptor beta 1; subcellular localization; overall survival; breast cancer
1. Introduction
Breast cancer (BC), the most frequent cause of cancer death worldwide [1], is highly heterogeneous,
leading to great complexity for diagnosis and therapy selection [2,3]. So far, only few diagnostic
markers are well recognized in invasive BC, including expression of the two nuclear receptors (NR),
the estrogen receptor (ER) and progesterone receptor (PR), and overexpression of human epidermal
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growth factor receptor 2 (HER2). Although therapies targeting ER and HER2 (e.g., tamoxifen and
trastuzumab) have been very successful, some tumors ultimately develop resistance to single or even
combination therapies [4]. Thus, the identification of other biomarkers is essential for optimal and
personalized BC management.
Links between BC and expression of other NR have already been outlined by our lab and
others [5–10]. Thyroid hormone receptors (THR) are members of the NR superfamily that mediate
the classical genomic actions of thyroid hormone (TH) signaling in numerous tissues and regulate
important physiological and developmental processes [11,12]. THR primarily act as ligand-dependent
transcription factors, after heterodimerization with retinoid X receptor (RXR). Various factors influence
TH activity, including THR mutations, interactions with heterodimerization partners and coregulators,
and expression of various THR subtypes and their related intracellular localization [13–15]. Indeed,
rapid shuttling of various THR isoforms between the nucleus and cytoplasm has been described,
and such dynamic transport pathways may be linked to specific TH signaling activities in nucleus,
cytoplasm, or mitochondria [11,12]. These properties have even led to a new classification scheme
with four TH signaling pathways; the canonical pathway, in which liganded THR binds directly to
DNA (type 1), is tethered to chromatin-associated proteins (type 2) or functions without recruitment to
chromatin either in the nucleus or cytoplasm (type 3). Finally, in the type 4 pathway, TH acts at the
plasma membrane or in the cytoplasm without binding THR [16].
A significant association between thyroid hormone (TH) signaling and BC has already been
demonstrated [17–19]. High TH levels are correlated with advanced clinical stages of BC [20].
A negative relationship between the presence of nuclear saturable high affinity binding sites of TH
and lymph node (LN) status of BC patients has also been known for decades. These binding sites
have been named thyroid hormone receptors (THRs) [21]. In a study performed at mRNA level in 116
breast samples, both THRα and THRβ mRNA levels were decreased in BC compared with normal
tissues; yet, only THRβ expression, and not that of THRα, was negatively associated with histological
grade [22]. Literature regarding the clinical significance of THR at the protein level is still limited.
A recent study performed in 41 invasive BC tissues suggested that nuclear THRα is down-regulated
during breast carcinogenesis [23]. Other studies highlighted the role of THRβ as a tumor suppressor in
BC. For instance, low THRβ expressing tumors were associated with poor outcome in triple negative
BC [24]. Lack of nuclear THRβ1 staining was reported in early stage BC and explained not only by
loss of heterozygosity, but also by THRβ1 promotor hypermethylation [25]. More recently, a study in
early BC demonstrated that THRβ1 expression is associated with long survival and is an independent
prognosis marker [26].
BC signaling and progression is also influenced by the complex interplay between NR,
their transcriptional coactivators, and corepressors that also have prognostic significance [27].
Among the transcriptional coregulators, RIP140 (receptor-interacting protein of 140 kDa) and LCoR
(ligand-dependent corepressor) play major roles in BC cell proliferation [7]. Moreover, we recently
analyzed RIP140 and LCoR expression at the protein level in BC biopsies, showing that expression
of these two proteins was highly correlated in more than 80% of tumors and that cytoplasmic
RIP140 expression was significantly correlated with a poor patient survival [9]. By sharing the same
heterodimerization partner and/or coregulators, other NRs such as peroxisome proliferator-activated
receptor γ (PPARγ) or vitamin D receptor (VDR) [6,28] may indirectly impact THR signaling.
While THRβ1 clearly appears to be a key player in BC carcinogenesis, the importance of its
subcellular localization remained to be elucidated. Therefore, purpose of this study was to analyze the
nuclear and cytoplasmic localization of THRβ1 in a well-defined cohort of 274 primary BC patients,
and to correlate the results with clinicopathological parameters and clinical outcome.
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2. Results
2.1. THRβ1 Expression in Primary Breast Cancers
The total cohort consisted of 274 samples from 271 primary BC patients (Table 1). Approval by
the Ethical Committee of the Medical Faculty, Germany had been granted and informed consent was
obtained from all patients, as described in Section 4.1. Median age at initial diagnosis was 57.0 years
(range 34.8–94.6 years); median follow-up between first diagnosis and last follow-up was 126 months
(range 4–153 months). During this period, 39 (14.2%) and 54 (19.7%) cases experienced either local
recurrence or distant metastases, respectively; 15 experienced both (5.7%); and 75 (27.4%) women died.
Table 1. Clinical and pathological characteristics of all patients.
Clinical and Pathological Characteristics a %
Median age (years, n = 274) b 57.00 range 34.79–94.62
Median follow up (months, n = 274) b 126 range 4–153
Histology c (n = 260)
No Special Type (NST) 139 53.46%
NST with DCIS 74 28.46%
Other invasive 47 18.08%
ER status (n = 272)
Positive 219 80.51%
Negative 53 19.49%
PR status (n = 272)
Positive 160 58.82%
Negative 112 41.18%
HER2 status (n = 273)
Positive 27 9.89%
Negative 246 90.11%
Molecular subtype (n = 273)
Luminal A (Ki-67 ≤ 14%) 152 55.68%
Luminal B (Ki-67 > 14%) 60 21.98%
HER2 positive luminal 20 7.33%
HER2 positive non luminal 7 2.56%
Triple negative 34 12.45%









Lymph node metastasis (n = 256)
Yes 112 43.75%
No 144 56.25%
Distant metastases d (n = 261)
Yes 54 20.69%
No 207 79.31%
Local recurrence (n = 261)
Yes 39 14.94%
No 222 85.06%
a All information refers to the primary tumor; b 3 of 271 patients have bilateral primary breast cancer (BC); here,
we consider each tumor as an individual one (n = 274); c NST include the formerly called “invasive ductal” and
“other” types; d distant metastasis was detected during the follow-up in 53 patients (1 of them is bilateral BC, so n =
54). DCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal
growth factor receptor 2; Ki67 (also known as MKI67) is a cellular marker for proliferation.
Expression of THRβ1 was analyzed by immunohistochemistry (IHC), using immunoreactive
scores (IRS) as described in Material and Methods. Distribution of staining intensities and percentages
of stained cells are presented in Supplemental Figure S1 (panels A and B). THRβ1 was widely expressed
and detected in 67.3% of the samples with predominantly nuclear location. Cytoplasmic staining also
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occurred and was quite strong in some cases. Distribution of IRS obtained either for nuclear (C) or
cytoplasmic (D) THRβ1 staining (n = 263 tumors stained) is presented in Supplemental Figure S1. It is
noteworthy that, for cytoplasmic THRβ1 staining, the highest IRS was 8. This was observed for only
two patients (exemplified in Figure 1A, enlarged in B); next to these two cases, 4 was the maximum
IRS observed. Consequently, panel C of Figure 1 shows one of the high cytoplasmic THRβ1 IRS (IRS 4).
In Figure 1, THRβ1 staining is illustrated for four patients with examples of absent or high expression,
and the respective nucleo–cytoplasmic IRS ratio. For extreme nuclear–cytoplasmic ratios (i.e., 0:0 and
12:8), enlarged photos are added (panels B and F).
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Figure 1. Immunohistochemical staining of thyroid hormone receptor β1 (THRβ1) in breast cancer 
samples. THRβ1 staining is illustrated for four patients (A,C–E) with examples of absent or high 
expression. Samples (A,E) are enlarged in panels (B,F), respectively. Nucleo–cytoplasmic IRS 
(immunoreactive score) ratios are indicated in each photomicrograph (25× magnification) and the 
scale bar equals 100 μm. 
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Using pairwise analysis, we first analyzed the correlation of THRβ1 expression with expression 
of other NR and coregulators (Table 3) with previously reported expression data [6,28–30]. We 
observed that both nuclear and cytoplasmic expression of THRβ1 was strongly positively correlated 
with expression of its heterodimerization partner RXR. We also searched for correlation with other 
NRs, namely, ER, PR, PPARγ, and VDR, and the coregulators LCoR and RIP140. We found no 
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THRβ1 distribution was then analyzed both in nucleus and in cytoplasm, and total expression
(sum of nuclear and cytoplasmic IRS) was calculated (Table 2). Nuclear staining was significantly
stronger than the cytoplasmic one (p < 0.05), although both means were quite low (1.41 and 1.30,
respectively). Nuclear THRβ1 staining was present in 60.5% of the tumors, and cytoplasmic THRβ1 in
43.3%. Interestingly, nuclear and cytoplasmic THRβ1 was significantly and positively correlated with
each other (r = 0.440 p < 0.01 using Spearman–Rho test).
Table 2. Distribution of thyroid hormone receptor β1 (THRβ1) expression.
Nuclear Cytoplasmic
Mean IRS ± SE 1.41 ± 0.11 1.30 * ± 0.11
Median IRS 1 0
IRS range 0–12 0–8
Number of samples with negative expression ** 104 (39.54%) 149 (56.65%)
Number of samples with positive expression ** 159 (60.46%) 114 (43.35%)
* Correlations were statistically significant for p < 0.05 (*), using Spearman–Rho test using mean bilateral analysis;
** negative defined as immunoreactive score (IRS) = 0, and positive expression as IRS > 0; SE = standard error
of means.
Distribution of tumors with negative or positive nuclear, or cytoplasmic, THRβ1 staining was
analyzed for all 263 tumors stained (Supplemental Table S1). It appeared that almost one-third of
the tumors were either negative (32.7%) or positive (36.5%) for both nuclear and cytoplasmic THRβ1
localizations. Regarding the nucleo–cytoplasmic ratio, 115 tumors (43.7%) had a ratio of 1, 80 tumors
(30.4%) had a ratio greater than 1 (i.e., more expression in the nuclear compartment), and 68 tumors
(25.9%) a ratio less than 1 (i.e., more expression in cytoplasm).
2.2. Correlation with Nuclear Receptor and Related Coregulators
Using pairwise analysis, we first analyzed the correlation of THRβ1 expression with expression of
other NR and coregulators (Table 3) with previously reported expression data [6,28–30]. We observed
that both nuclear and cytoplasmic expression of THRβ1 was strongly positively correlated with
expression of its heterodimerization partner RXR. We also searched for correlation with other NRs,
namely, ER, PR, PPARγ, and VDR, and the coregulators LCoR and RIP140. We found no correlation
with ER and PR, but saw a strong correlation between nuclear and cytoplasmic THRβ1 and PPARγ.
In contrast, only cytoplasmic THRβ1 was significantly correlated with VDR.
Table 3. Correlation between THRβ1 expression and nuclear receptors and related coregulators.
n References Nuclear Cytoplasmic
RXR 246 [28,30] 0.256 ** 0.186 **
ER 262 0.043 −0.115
PR 262 0.085 −0.014
PPARγ 247 [28,30] 0.315 ** 0.247 **
VDR 248 [28] −0.097 −0.155 *
LCoR 257 [9]
Nuclear 0.011 −0.060
Cytoplasmic 0.110 0.221 **
RIP140 258 [9]
Nuclear 262 0.027 −0.046
Cytoplasmic 262 −0.009 0.029
Correlations are statistically significant for p < 0.05 (*) or p < 0.01 (**), using Spearman–Rho test. RXR, retinoid X
receptor; PPARγ, peroxisome proliferator-activated receptor γ; VDR, vitamin D receptor; LCoR, ligand-dependent
corepressor; RIP140, receptor interacting protein of 140 kDa.
We previously investigated the expression of two NR transcriptional coregulators, namely RIP140
and LCoR, and demonstrated that their sub-cellular localization may define their association with BC
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aggressiveness and survival [9]. Regarding THRβ1, only cytoplasmic expression of the transcriptional
coregulator LCoR was positively correlated with cytoplasmic THRβ1. No significant association was
observed with RIP140.
2.3. Correlation with Clinicopathological Parameters
Correlations between THRβ1 expression and known clinicopathological characteristics, besides
ER and PR, were also analyzed. CD133, a widely used marker for isolating cancer stem cells [31,32],
and N-cadherin, a well-known marker for epithelial-to-mesenchymal transition [33], are associated
with BC aggressiveness; we previously reported quantification of their expression in the same BC
cohort [34]. As shown in Table 4, both nuclear and cytoplasmic THRβ1 expression were significantly
and positively correlated with CD133 and N-cadherin (NCAD). Nonetheless, only cytoplasmic THRβ1
expression was positively correlated with proliferation marker Ki67 and HER2, but negatively with
tumor size. No further significant correlation between the clinicopathological characteristics mentioned
in Table 1 and THRβ1 expression was found.
Table 4. Correlation between THRβ1 expression and clinicopathological markers. HER2, human
epidermal growth factor receptor 2; NCAD, N-cadherin.
n Nuclear Cytoplasmic
pT 251 −0.023 −0.151 *
pN 247 0.044 −0.066
Grade 145 0.128 0.101
HER2 status 262 0.080 0.131 *
Triple negative 263 −0.052 0.031
Ki67 204 0.089 0.225 **
CD133 240 0.183 ** 0.178 **
NCAD 244 0.342 ** 0.327 **
Correlations are statistically significant for p < 0.05 (*) or p < 0.01 (**), using Spearman–Rho test; CD = cluster
of differentiation.
2.4. Correlation between THR Expression and Patient Outcome
In order to analyze the correlation between THRβ1 and patient outcome, we performed
Kaplan–Meier analyses (Figure 2). Instead of the simple negative/positive cut-off (Table 2),
we determined optimal IRS cut-off values for overall survival (OS) using receiver operating characteristic
(ROC)-curve analysis, thus allowing maximum difference between sensitivity and specificity parameters.
We then divided the tumors in low or high expressing subgroups for all survival analyses.
As shown in Figure 2A,B, neither nuclear nor cytoplasmic THRβ1 had any significant correlation
with relapse-free survival (RFS), for various IRS cut-off values tested. Nonetheless, there was an
opposite trend regarding RFS; nuclear THRβ1 expression was related to poor outcome and cytoplasmic
expression to favourable outcome. Analyzing OS (Figure 2D,E), we found that the nuclear THRβ1 was
significantly correlated with poor outcome, while cytoplasmic THRβ1 was significantly correlated with
favourable outcome (p = 0.038 and 0.015, respectively). Analyzing total THRβ1 expression of (sum of
nuclear and cytoplasmic IRS), no correlation with RFS (Figure 2C) nor OS (Figure 2F) was found.
To determine the specificity of this result (opposite correlations of nuclear and cytoplasmic
THRβ1 expression with OS), we performed the identical analyses with another THR, namely THRα2,
in the same cohort (staining in Supplemental Figure S2; distribution in Supplemental Table S2).
Analyzing OS according to nuclear and cytoplasmic THRα2 expression (Supplemental Figure S3),
we could demonstrate, as expected, a significant beneficial effect of nuclear THRα2 on OS (panel
A). Yet, cytoplasmic THRα2 expression did not have any significant correlation with OS (panel B).
These additional analyses suggest that the opposite impact on outcome observed for cytoplasmic and
nuclear THRβ1 expression may not be true for all THR isoforms.
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2.5. Nuclear and Cytoplasmic THRβ1 Expression as Independent Prognostic Parameters for OS
Finally, we performed multivariate analyses using the Cox regressi n model with cytoplasmic
and nuclear THRβ1 expression and four relev nt clinicopatholog cal features (age at time of diagnosis,
tumor size, ER-, an HER2 status). As shown in Table 5, we found that age, tu or size, and ER wer
independent prognostic markers for OS. As xpected, the cytoplasmic form of THRβ1 expression
appeared to be an indep nde t prognostic m rker for OS with a h zard ra io of 0.545, confirming
its correlation with favorable outcome. Inter stingly, nuclear THRβ1 expr ssi n was shown as an
independent progno tic marker for poor OS; with a hazard ratio of 2.860 indicating a higher risk of
death for patients whose tumors express high levels of nuclear THRβ1.
Table 5. Multivariate analysis (OS, overall survival) of clinicopathological variables and THRβ1.
Variable p-Value HR (95% CI)
Age 0.000007 *** 1.042 (1.023–1.061)
pT 0.0000002 *** 3.701 (2.256–6.073)
ER 0.001 ** 0.408 (0.242–0.687)
HER2 0.209 1.566 (0.778–3.153)
Cytoplasmic THRβ1 0.048 * 0.545 (0.299–0.995)
Nuclear THRβ1 0.0004 ** 2.860 (1.597–5.119)
Hazard ratios (HRs) are indicated with 95% confidence intervals (CIs). Correlations are statistically significant for
p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***).
3. Discussion
The aim of this study was to characterize THRβ1 expression in a wide range of primary BC tissues,
taking into account its intracellular expression, and to correlate the results with clinicopathological
parameters and patient outcome.
Our study confirmed that THRβ1 is expressed with a predominantly nuclear location, as previously
described for most THR isoforms. Nonetheless, our results also demonstrate cytoplasmic localization
of THRβ1 in BC. THs are able to modulate gene expression by binding to THRα either in the cytoplasm
or in the nucleus of the cells [35]. It is also known that THR can be present not only in the nucleus,
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but also in the cytoplasm and in the mitochondria [12]. T3 can also be associated to plasma membrane
structural α5β3 integrin, thereby regulating cell–cell and cell–extracellular matrix interactions and
changing the morphology of BC cells [36]. Our results are supported by a previous study reporting
cytoplasmic expression of THRβ1. In a large cohort of early BC patients, THRβ1 expression was
predominantly found in the cytoplasm [26]. In most studies, however, including ours, THRβ1
expression is predominantly nuclear. We are aware that the different antibodies used in each study
may explain substantial differences in expression. Nonetheless, in another study, THRβ was described
as being expressed in nuclei of proliferative cells, in in situ carcinoma, and in the cytoplasm in normal
breast and in infiltrative BC cells [37].
The second major observation provided by our study is that nuclear and cytoplasmic forms of
THRβ1 may exhibit opposite roles in breast tumorigenesis. Indeed, considering the correlation with
patient survival (Figure 2), cytoplasmic expression consistently behaved opposite to nuclear expression.
These correlations are strengthened by the fact that nuclear THRβ1 is an independent prognostic marker
for poor outcome in multivariate analysis, whereas cytoplasmic THRβ1 is an independent prognostic
marker for favorable outcome (Table 5). The only other study that took the subcellular localization
of THRβ1 expression into account (n = 796) [26] focused solely on cytoplasmic THRβ1, but did not
consider nuclear expression. It should be noted that, in our study, both nuclear and cytoplasmic THRβ1
expression correlate with the heterodimerization partner, RXR, but only cytoplasmic THRβ1 correlates
with VDR and cytoplasmic LCoR. Consequently, mere analysis of nuclear THRβ1expression, although
this is the predominant expression, does not allow a complete understanding of the relevance of both
expression types. Considering the subcellular THRβ1 localization seems to be essential for further
analysis of its impact on patient outcome. A recent in vitro study suggested a novel role of THRβ,
namely THRβ1, in the biology of cancer stem cells that could explain its action as a tumor suppressor
in BC [38]. In our study, both nuclear and cytoplasmic THRβ1 strongly correlate positively with CD133
and N-cadherin, without any differential effect according to their subcellular location.
Concerning the link with ER, the study by Jerzak et al. [26] reported a correlation of cytoplasmic
THRβ1 with favorable outcome only in ER-positive BC. Although we did not see a significant correlation
between ER expression and nuclear or cytoplasmic THRβ1 expression (Table 3), we confirmed that
cytoplasmic THRβ1 expression was correlated with good outcome in ER-positive tumors (p = 0.021),
but not in ER-negative ones (p = 0.161) (Supplemental Figure S4A,B). Consequently, we demonstrated
that cytoplasmic THRβ1 expression was also correlated with good outcome in luminal tumors
(p = 0.035), but not in non-luminal ones (p = 0.142) (Supplemental Figure S4C,D). Yet, when we stratified
our cohort according to ER expression, nuclear THRβ1 was no longer correlated with OS in either
subgroup (data not shown). Further investigations are needed to define the link between cytoplasmic
THRβ1 and estrogen signaling in BC cells at the molecular level.
Our results also suggest that the differential impact on outcome depending on nuclear or
cytoplasmic THRβ1 localization is not a common feature for all THRs. In the present study, we also
analyzed THRα2 expression. Previously, we had demonstrated that nuclear THRα2 expression tends
to be an independent and favorable prognostic marker for survival in a small cohort of 82 invasive BC
cases [39]. This was confirmed in another cohort of 130 invasive BC samples, where THRα2 (nuclear
and cytoplasmic) negatively correlated with HER2 status, and positively with ER/PR and favorable
OS [40]. In the present work, we confirmed that nuclear THRα2 was significantly correlated with
a favorable prognosis. Interestingly, we did not find any inverse correlation of cytoplasmic THRα2
expression with OS (Supplemental Figure S3). Taken together, our data suggest a specific role of each
subcellular expression only for THRβ1.
In summary, the present study confirms the complexity of the links between subcellular localization
of the THRβ1 protein and its association with patient outcome. To our knowledge, it is the only study
supporting the fact that the nuclear form of THRβ1, probably acting as a classical ligand-dependent
transcription factor, may have tumor-promoting effects in BC. Our results emphasize the importance
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of more precise investigations of the subcellular localization of THRs in order to define their impact as
potential biomarkers in breast cancer.
4. Materials and Methods
4.1. Patient Cohort
A total of 274 formalin-fixed paraffin-embedded primary BC tissues were collected from 271
patients (3 of them with bilateral BC) who underwent surgery between 2000 and 2002 at the Department
of Obstetrics and Gynecology of the Ludwig-Maximilians-University Munich, Germany. All patient
data and clinical information from the Munich Cancer Registry were fully anonymized and encoded
for statistical analysis. Research was approved by the Ethical Committee of the Medical Faculty,
Ludwig-Maximilian-University (LMU), Munich, Germany (approval number 048-08; 18 March 2008)
and informed consent was obtained from all patients. Union for International Cancer Control (UICC)
TNM classification was performed to evaluate the size and extent of the primary tumor (pT), lymph
node involvement (pN), and distant metastasis (M). Tumor grade was determined by an experienced
pathologist (Dr D. Mayr) of the LMU Department of Pathology, according to a modification of Elston
and Ellis grading proposed by Bloom and Richardson [41]. ER, PR, HER2, Ki67, and histological status
were determined by an experienced pathologist (LMU Department of Pathology), as described below.
HER2 2+ scores were further evaluated through fluorescence in situ hybridization (FISH) testing.
4.2. Immunohistochemistry (IHC)
Expression of ERα and PR was determined at diagnosis in all BC samples of this cohort at the LMU
Department of Pathology, Germany. ERα and PR expression were evaluated by IHC, as previously
described [6,30]. Samples showing nuclear staining in more than 10% of tumor cells were considered
as hormone receptor-positive, in agreement with the guidelines at the time of analysis (2000–2002).
HER2 expression was later analyzed using an automated staining system (Ventana; Roche, Mannheim,
Germany), according to the manufacturer’s instructions. Ki67 was stained using an anti-Ki67
monoclonal antibody (Dako, Hamburg, Germany) at a dilution of 1:150 on a VENTANA®-Benchmark
Unit (Roche, Mannheim, Germany) as previously described [28]. The Ki67 cut-off used to differentiate
luminal A from luminal B tumors (all HER2 negative) was 14%, as this was commonly used at the
time of the analysis, although 20% is now preferred [42]. We performed paired-analysis, and used
data on N-cadherin and CD133 expression in these BC samples extracted from a previously published
study [34], as well as RXR, VDR and PPARγ [28,30], and RIP140 and LCoR [9]. For THRα and THRβ1
analysis by IHC, samples were processed as previously described [9,10,30,34,39,43]. All sections were
first cut and prepared from paraffin-embedded BC samples using standard protocols. Phosphate
buffered saline (PBS) was used for all washes and sections were incubated in blocking solution
(ZytoChem Plus HRP Polymer System Kit, ZYTOMED Systems GmbH, Berlin, Germany) before
incubation with primary antibodies. All primary antibodies were rabbit IgG polyclonal: anti- both
THRα1 and THRα2 (immunogen being a synthetic peptide corresponding to a region within internal
sequence amino acids 246–295 of human thyroid hormone receptor alpha 1 and 2, Abcam, ab 105003,
Cambridge, UK) and anti-THRβ1 (immunogen being a synthetic peptide within amino acids 1–100 of
the N-terminus of human TR-beta protein, Zytomed, 520-4074, Berlin, Germany). Isoform specific
antibodies against THRα2 have been used for Supplemental Figure S2, namely a monoclonal mouse
one against the N-terminus region of THRα2 (MCA 2842, AbD Serotec, Oxford, UK).
After incubation with a biotinylated secondary anti-rabbit or anti-mouse IgG antibody,
and with the associated avidin–biotin–peroxidase complex (both Vectastain Elite ABC Kit; Vector
Laboratories, Burlingame, CA, USA), visualization was performed with substrate and chromogen 3,
3-diamino-benzidine (DAB; Dako, Glostrup, Denmark). Negative and positive controls were used to
assess the specificity of the immunoreactions. Negative controls (colored in blue) were performed
in BC tissue by replacement of the primary antibodies by species-specific (rabbit/mouse) isotype
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control antibodies (Dako, Glostrup, Denmark). Appropriate positive controls (placenta samples) were
included in each experiment. Sections were counterstained with acidic hematoxylin, dehydrated,
and immediately mounted with Eukitt (Merck, Darmstadt, Germany) before manual analysis with a
Diaplan light microscope (Leitz, Wetzlar, Germany) with 25×magnification. Pictures were obtained
with a digital Charged Coupled Device (CCD) camera system (JVC, Tokyo, Japan). All slides were
analyzed by two or three independent examiners.
4.3. Immunoreactive Score (IRS)
Expression of THRβ1 and THRα2 was assessed according to IRS, determined by evaluating the
proportion of positive tumor cells, scored as 0 (no staining), 1 (≤10% of stained cells), 2 (11%–50%
of stained cells), 3 (51%–80% of stained cells), and 4 (≥81% of stained cells); as well as their staining
intensity, graded as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong) (IRS = percentage score ×
intensity score), as presented in Supplemental Figure S1 (panels A and B). Thus, IRS values range
from 0 to 12. As previously described for LCoR and RIP140 [9] and for AhR [10], cytoplasmic and
nuclear staining of THRβ1 and THRα2 were evaluated in parallel, with a separate determination
of cytoplasmic IRS and nuclear IRS. For all other markers, staining and IRS were determined in the
whole cells, without differentiation of nuclear and cytoplasmic staining. A total of one hundred cells
(three spots with around thirty cells each) was analyzed for each sample and the IRS corresponded
to the mean of the IRS determined on the three spots. The intensity and distribution pattern of the
immunochemical staining reaction was evaluated by two independent blinded observers. In five cases
(2% of the total), the evaluation of the two observers differed. These cases were re-evaluated by both
observers together. After the re-evaluation, both observers agreed on the result. The concordance
before the re-evaluation was 98.0%.
4.4. Statistical and Survival Analysis
Statistical analyses were performed using software package used for interactive, or batched,
statistical analysis (SPSS) 24 (IBMSPSS Statistics, IBM Corp., Armonk, NY, USA). For all analyses,
p values below 0.05 (*), 0.01 (**), or 0.001 (***) were considered statistically significant. Differences in
Table 2 were calculated using mean or percentage bilateral analysis. Receiver operating characteristic
(ROC) curve analyses were performed to calculate the optimal cut-off values between low and high
THRβ1 and THRα2 expressions, based upon the maximal differences of sensitivity and specificity.
The threshold determined regarding OS was an IRS ≥ 2.5 for nuclear THRβ1, ≥1.5 for cytoplasmic
THRβ1, ≥1.5 for cytoplasmic THRα2, and ≥0.5 for nuclear THRα2.
Correlation analyses presented in Tables 3 and 4 were performed by calculating the Spearman–Rho
correlation coefficient (p values of Spearman–Rho test presented), using pairwise analysis. Survival
times were compared by Kaplan–Meier graphics and differences in RFS and OS were tested for
significance using the chi-square statistics of the log rank test. Data were assumed to be statistically
significant in the case of p-value <0.05 or <0.01. Kaplan–Meier curves and estimates were then provided
for each group and each marker. The p value and the number of patients analyzed in each group are
given for each chart.
The multivariable analysis for outcome (OS) presented in Table 5 was performed using the
Cox regression model and included nuclear and cytoplasmic of THRβ1 expressions and relevant
clinicopathological characteristics as independent variables. Variables were selected based on theoretical
considerations and forced into the model. p values and hazard ratios were indicated, knowing that the
hazard ratios of covariates are interpretable as multiplicative effects on the hazard, and holding the
other covariates constant.
5. Conclusions
Although THRβ1 was predominantly expressed in tumor cell nuclei in our primary BC cohort,
cytoplasmic expression was also detected; its correlation with patient survival was inverse to that
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of nuclear THRβ1. Our results demonstrate that THRβ1 may have different roles in tumorigenesis
according to its subcellular localization. A major conclusion is also that THR, particularly nuclear
THRβ1, can exhibit tumor-promoting activities in the mammary gland, as demonstrated by its
independent prognostic value.
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AhR aryl hydrocarbon receptor
BC breast cancer
CI confidence interval
DCIS ductal carcinoma in situ
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pN primary lymph node
PPARγ peroxisome proliferator-activated receptor γ
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RIP140 receptor interacting protein of 140 kDa
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